| Date | Title | Description | |
|---|---|---|---|
| 23 Feb 2022 | On business and financial situation | The Company releases the full year 2021 financial results presentation | Download |
| 23 Feb 2022 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 22 Feb 2022 | On buy-back programmes | ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022. | Download |
| 16 Feb 2022 | On business and financial situation | Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years | Download |
| 03 Nov 2021 | On buy-back programmes | The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 10 May 2023 | Announcement of General Shareholders’ Meeting | ROVI releases the information related to its General Shareholders Meeting | Download |
| 10 Apr 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the first quarter of 2023 | Download |
| 21 Feb 2023 | Annual Corporate Governance Report | ROVI releases the 2022 Annual Corporate Governance Report | Download |
| 21 Feb 2023 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2022 annual report regarding remuneration of the members of the Board of Directors | Download |
| 16 Feb 2023 | On business and financial situation | The Company informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 04 Oct 2018 | Share capital increases and reductions | Private placement capital increase addressed to institutional investors, excluding preferential subscription rights | Download |
| 02 Oct 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the third quarter of 2018 | Download |
| 24 Sep 2018 | Others on business performance and financial information | Updated information on business, financial position and risk factors | Download |
| 24 Sep 2018 | Share capital increases and reductions | Intention to raise gross proceeds by means of an offer addressed to institutional investors, excluding preferential subscription rights | Download |
| 26 Jul 2018 | Información sobre resultados | ROVI releases the 2018 first half results presentation | Download |